NOVO NORDISK: | NEUTRAL, DKK358 vs. DKK350 | Without any new data, Novo-Nordisk leaves ADA 2019 stronger
NOVO NORDISK - | Without any new data, Novo-Nordisk leaves ADA 2019 strongerOral semaglutide increasingly looks like new SoC
Our biggest concern remains competition for Ozempic
Lilly’s tirzepatide less of a threat than initially thought?
Conclusion
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.